Effect of Topical Tacrolimus in the Treatment of Thygeson's Superficial Punctate Keratitis

Marquezan, Maria Carolina; Nascimento, Heloísa; Vieira, Luis Antonio; Serapião, Myrna; Ghanem, Ramon Coral; Belfort, Rubens; Freitas, Denise de

doi:10.1016/j.ajo.2015.06.019

Cited by 16 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both are used as treatment for Thygeson's superficial punctate keratitis, graft vs. host disease, Sjogren's syndrome, and other severe ocular surface inflammations [6]. We report use of these immunomodulators and steroids as adjunctive therapy to reduce marked surface inflammation in a case of successful repair of early shunt plate erosion.…”

Section: Discussionmentioning

confidence: 99%

A Successful Early Postoperative Shunt Plate Erosion Repair-Case Report

Joos¹

2015

AOVS

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A Successful Early Postoperative Shunt Plate Erosion Repair-Case Report

Joos¹

2015

AOVS

View full text Add to dashboard Cite

“…Both of these agents were proven effective in numerous studies having beneficial effect in the management of immune mediated ocular surface disorders including TSPK, with no steroid induced side effects in the long run. 13,[15][16][17][18][19] However, the immuno-suppressive activity of TCL is superior to cyclosporine-A. 16 TCL also gets better and rapid absorption into corneal and conjunctival tissues.…”

Section: Thygeson Superficial Punctate Keratitismentioning

confidence: 99%

“…16 TCL also gets better and rapid absorption into corneal and conjunctival tissues. 18 In the quest for exploration of topical TCL ointment 0.03% in the treatment of TSPK, one study concluded that ointment has the advantage over eye-drops due to prolonged ocular retention and contact resulting in better tissue absorption and bioavailability, but it increases the incidence of ocular surface irritation comparatively. Two out of 12 patients included in his study developed transient FB-sensation and stinging in eyes.…”

Section: Thygeson Superficial Punctate Keratitismentioning

confidence: 99%

Efficacy and safety of topical tacrolimus 0.03% ointment in thygeson superficial punctate keratitis.

Ahmad

Haq²,

Hussain³

et al. 2023

TPMJ

View full text Add to dashboard Cite

Objective: To assess the effectiveness of topical tacrolimus (TCL) 0.03% dermatological ointment in the treatment of patients with Thygeson superficial punctate keratitis. Study Design: Retrospective Review. Setting: Eye OPD of Qazi Hussain Ahmad Medical Complex, Nowshera. Period: Jan 2019 to Jan 2021. Material & Methods: Twelve patients with Thygeson superficial punctate keratitis (TSPK) were included retrospectively by reviewing their medical records. Eight patients were unresponsive to topical steroids and/or lubricants. Diagnosis was made based on the history and clinical findings. All patients were treated with topical tacrolimus 0.03% dermatological ointment twice a day. We took the following subjective features for assessment i.e. watering of eyes and light sensitivity, while for objective features reduction in the no. of epithelial keratitis, healing of keratitis, surface leveling of the lesion and reduced corneal staining with fluorescein. Results: Out of total 12 patients, 4 were male and 8 females with a mean age of 21 ± 9.42 years. All were having bilateral involvement. Duration of therapy ranged from 02 to 40 weeks (mean 08 weeks). All patients improved symptomatically with resolution of watering of eyes and light sensitivity, while in ocular signs we noted improvement in corneal lesions. The efficacy of therapy was observed 3 days, post application among all patients. No, side effects reported in any of our patients treated with topical TCL dermatological ointment. Conclusion: The safety and efficacy of topical tacrolimus 0.03% dermatological ointment has been observed in patients with Thygeson superficial punctate keratitis who were refractory to conventional therapy.

show abstract

“…The clinical evolution is heterogeneous as some patients present with remittent-recurrent disease with variable delay between recurrences, while some suffer from chronic disease, with persistent activity over years [1]. For patients with frequent recurrences or chronic disease, topical corticosteroid and immunosuppressants such as cyclosporine A (CSA) and tacrolimus seem a good option, suggesting involvement of underlying immunologic mechanisms [8][9][10]. However, there are currently no validated criteria to clearly define group of patients according to the clinical course and severity.…”

Section: Introductionmentioning

confidence: 99%

Using pre-existing social networks to determine the burden of disease and real-life needs in rare diseases: the example of Thygeson's superficial punctate keratitis

Saad

Haigh

et al. 2021

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background Thygeson’s superficial punctate keratitis (TSPK) is a rare and still poorly understood disease of the ocular surface, responsible for recurrent episodes of photophobia and eye pain. While TSPK is considered as a benign condition, a subset of patients has frequent recurrences or even chronic disease, two situations in which there are currently no therapeutic guidelines. We used a preexisting Facebook TSPK patient support group to assess the clinical journey and the burden of disease of TSPK. Results An online survey was sent to the patient support group. The first part of the questionnaire gathered information on demographics and the patient’s clinical journey [diagnostic modalities, symptoms, duration and frequency of recurrent episodes (RE), efficacy and tolerance to treatments]. The second part focused on quality of life (QoL) using the Ocular Surface Disease-QoL (OSD-QoL) questionnaire. Seventy-two patients out of 595 members of the support group completed the questionnaire during the 3-months study period. Eighty percent of patients developed symptoms before 30 years old, and 47% reported a delay in the diagnosis above 1 year. Sixty percent of patients reported over 5 RE yearly, and 18% of RE lasted more than 3 months. Forty percent of all patients used cyclosporine eyedrops (50% of those with > 5 episodes/year) and it was perceived as effective by 72% of these patients. The impact on daily life activities was judged as severe by 22% of patients, while 38% reported reduced professional activity and 80% were deeply saddened by their eye condition. Conclusion TSPK patients may present with frequent recurrences and/or chronic disease, that result in a severe impact on QoL, and an off-label use of topical immunomodulatory eye drops, suggesting the urgent need for controlled studies. The utility of using social networks for rare ophthalmic disease research includes, faster data collection, data from patients across the globe, and also raises relevant questions about their real needs.

show abstract

Effect of Topical Tacrolimus in the Treatment of Thygeson's Superficial Punctate Keratitis

Cited by 16 publications

References 39 publications

A Successful Early Postoperative Shunt Plate Erosion Repair-Case Report

A Successful Early Postoperative Shunt Plate Erosion Repair-Case Report

Efficacy and safety of topical tacrolimus 0.03% ointment in thygeson superficial punctate keratitis.

Using pre-existing social networks to determine the burden of disease and real-life needs in rare diseases: the example of Thygeson's superficial punctate keratitis

Contact Info

Product

Resources

About